Mark Peterson

Michelin is acquiring Cooley Group and Tex Tech Industries, pushing deeper into advanced materials for aerospace and healthcare as part of its 2030 strategy.

The crypto payment firm rolled out Ethereum and BNB support, a new Bitcoin explorer, and developer tools in a pivotal year. Is it enough to challenge the giants?

Dr. Lu Xianping, crowned EY Entrepreneur Of The Year, didn't just invent new drugs; he helped reinvent China's entire pharmaceutical industry.

Cannabix Technologies lands its first international order for its smart breathalyzer in Australia, a move that validates its tech and reshapes its finances.

As Aircastle prepares its Q3 2025 results, all eyes are on the leasing giant for insights into the supercharged global aviation finance sector.

Euromax Resources raised C$1.6M, but with 84% for overhead and only 9% for its stalled gold project, is this a step forward or just staying afloat?

New Era Energy & Digital faces a major fraud lawsuit from New Mexico over abandoned oil wells, threatening its pivot to a high-tech data center future.

The popular brunch chain is betting on a digital marketing guru to transform its customer experience and accelerate growth in a tech-driven market.

From a huge 10-restaurant deal to stadium snacks, The ONE Group reveals a capital-efficient playbook for expanding its Benihana and STK brands.

WISeKey's satellite arm, WISeSat, is merging with a SPAC to build a quantum-resilient IoT network, a key step in securing future global communications.

The semiconductor equipment firm will release crucial 2025 and 2026 financial guidance in January, offering a key early test of the industry's momentum.

A relaunched driver's ed franchise is tackling teen safety with a unique local strategy. See how one leader's playbook is empowering franchisees nationwide.

Casey Plummer's appointment signals NDBT's strategic focus on Dallas's property market and a deeper commitment to community-led development initiatives.

Alvotech and Teva's settlement with Regeneron for an Eylea biosimilar paves the way for a 2026 launch, promising increased competition and lower costs.

A new settlement positions a cost-effective alternative to the blockbuster eye drug Eylea for a 2026 U.S. launch, signaling intense market disruption.

Nova Minerals is raising $20M to advance its Estelle Project, a key Alaskan site for gold and the strategically vital mineral antimony amid global supply woes.

A new oral drug, cadisegliatin, enters a major clinical trial in the UAE, aiming to help Type 2 diabetes patients struggling with insulin therapy.

A monumental shift in U.S. drug policy as cannabis is rescheduled. See what this means for Verano, Wall Street, and the future of the industry.

Facing financial headwinds, Celularity lands a critical $12M from a top investor to push its ambitious anti-aging and regenerative therapies forward.

A simple, low-cost heart pill may hold the key to treating Alzheimer's and kidney disease. CardioPharma is now funding research to unlock its potential.